In vitro activities of daptomycin against 2,789 clinical isolates from 11 north american medical centers

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 6, 2001, Pages 1919-1922

  Barry, Arthur L ^a,b   Fuchs, Peter C ^a   Brown, Steven D ^a  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; DAPTOMYCIN; MAGNESIUM ION; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; SERUM;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA;

EID: 0035007793     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.6.1919-1922.2001     Document Type: Article

References (10)

1. Eliopoulos, G. M., S. Willey, E. Reiszner, P. G. Spitzer, G. Caputo, and R. C. Moellering. 1986. In vitro and in vivo activity of LY146032, a new cyclic lipopeptide antibiotic. Antimicrob. Agents Chemother. 30:532-535.
2. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2000. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn. Microbiol. Infect. Dis. 38:51-58.
3. Jones, R. N., and A. L. Barry. 1987. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility lest recommendations. Antimicrob. Agents Chemother. 31:625-629.
4. Kennedy, S., and H. F. Chambers. 1989. Daptomycin (LY 146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrob. Agents Chemother. 33:1522-1525.
5. Louie, M., A. E. Simor, S. Szeto, M. Patel, B. Kreisworth, and D. E. Low. 1992. Susceptibility testing of clinical isolates of Enterococcus faecalis and Enterococcus faecium. J. Clin. Microbiol. 30:41-45.
6. Low, D. E., A. McGeer, and R. Poon. 1989. Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility test recommendations. Antimicrob. Agents Chemother. 33:585-588.
7. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, fifth edition. Approved standard M7-A5. NCCLS, Wayne, Pa.
8. Ramas, M. G., M. L. Grayson, G. M. Eliopoulos, and A. S. Bayer. 1992. Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci. Antimicrob. Agents Chemother. 36:1864-1869.
9. Ryback, M. J., E. M. Bailey, K. C. Lamp, and G. W. Kaatz. 1992 Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravascular drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob. Agents Chemother. 36:1109-1114.
10. Tally, F. P., M. Zeckel, M. M. Waselewski, C. Carini, C. L. Berman, G. L. Drusano, and F. B. Oleson. 1999. Daptomycin: a novel agent for Grampositive infections. Exp. Opin. Investig. Drugs 8:1223-1238.